Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06608641 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients
A Phase 3 study of Bipolar 1 Disorder, sponsored by Jina Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 490
- Enrollment target
- 12
- Study locations
NCT06608641 is a Phase 3 study of Bipolar 1 Disorder that is active but no longer recruiting, run by Jina Pharmaceuticals. The registered enrollment target is 490 participants, above the 356-participant average among 3 other Bipolar 1 Disorder trials with a reported enrollment target (38% higher). The trial reports 12 study locations across 4 states.
The verdict
NCT06608641, a Phase 3 study of Bipolar 1 Disorder, is active but no longer recruiting, sponsored by Jina Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 490 participants
- Enrollment target
- 12
- Study locations
Study Summary
Bipolar disorder (BPD) is a chronic debilitating illness characterized by drastic swings in mood, energy and functional ability that affects the adult population. Endoxifen is an active metabolite of the marketed drug Tamoxifen and the present study aims to evaluate the efficacy and safety of 8 mg endoxifen in the Bipolar I disorder patient population compared to a placebo arm. Endoxifen will be compared to a placebo to demonstrate that the test product is active and to establish that the study is sufficiently sensitive to detect differences between the investigational products. Thus, Endoxifen will be compared to placebo to demonstrate that the test product is safe and active.
Conditions Studied
Interventions
- DRUG Placebo Tablets
- DRUG Endoxifen enteric-coated tablet (8 mg)
Study Locations (12)
Florida
- Medical Research of Westchester, Inc. - Miami
- Sunshine Medical Research Studies Inc. - Miami
- Innovative Clinical Research, Inc. - Miami Lakes
- South Florida Research Phase I-IV, Inc. - Miami Springs
- Santos Research Center, CORP - Tampa
California
- Synexus - Cerritos
- NRC Research Institute - Los Angeles
- NRC Research Institute - Orange
Georgia
- Accelerated Clinical Trials, LLC - East Point
- Accelerated Clinical Trials, LLC - Norcross
- Accelerated Clinical Trials, LLC - Peachtree Corners
Mississippi
- Precise Research Centers - Flowood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 490 participants |
| Start Date | 2024-03-19 |
| Est. Completion | 2025-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06608641
The ClinicalTrials.gov registry entry for NCT06608641 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 490 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 356-participant average among 3 other Bipolar 1 Disorder trials with a reported enrollment target (38% higher). The listed sponsor is Jina Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bipolar 1 Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo Tablets is the first listed.
NCT06608641 reports 12 study locations spanning 4 distinct geographic areas - top geographies include Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT06608641 about?
NCT06608641 is a clinical study titled "Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients". Bipolar disorder (BPD) is a chronic debilitating illness characterized by drastic swings in mood, energy and functional ability that affects the adult population. Endoxifen is an active metabolite of the marketed drug Tamoxifen and the present study aims to evaluate the efficacy and safety of 8 mg e...
What is the current status of trial NCT06608641?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 490 participants. The study started on 2024-03-19. Estimated completion is 2025-12.
What conditions does trial NCT06608641 study?
This clinical trial studies the following conditions: Bipolar 1 Disorder.
What interventions are being tested in trial NCT06608641?
The interventions under investigation include: Placebo Tablets (DRUG), Endoxifen enteric-coated tablet (8 mg) (DRUG).
Who is sponsoring clinical trial NCT06608641?
This trial is sponsored by Jina Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06608641 being conducted?
This trial has 12 study locations across California, Florida, Georgia, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar 1 Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.